Question

In: Finance

After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market....

After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market. It is considering two alternative products. The first is a medication for headache pain. The second is a pill for headache and arthritis pain. Both products would be introduced at a price of $8.50 per package in real terms. The headache-only medication is projected to sell 3 million packages a year, whereas the headache and arthritis remedy would sell 4.7 million packages a year. Cash costs of production in the first year are expected to be $4.25 per package in real terms for the headache-only brand. Production costs are expected to be $4.80 in real terms for the headache and arthritis pill. All prices and costs are expected to rise at the general inflation rate of 2 percent.

  

Either product requires further investment. The headache-only pill could be produced using equipment costing $27 million. That equipment would last three years and have no resale value. The machinery required to produce the broader remedy would cost $30 million and last three years. The firm expects that equipment to have a $1,100,000 resale value (in real terms) at the end of Year 3.

  

The firm uses straight-line depreciation and has a tax rate of 23 percent. The appropriate real discount rate is 8 percent.

  

a.Calculate the NPV for headache pain reliever only. (Do not round intermediate calculations and enter your answer in dollars, not millions of dollars, rounded to 2 decimal places, e.g., 1,234,567.89.)

b.Calculate the NPV for headache and arthritis pain reliever. (Do not round intermediate calculations and enter your answer in dollars, not millions of dollars, rounded to 2 decimal places, e.g., 1,234,567.89.)

Solutions

Expert Solution

Solution:

a)Calculation of NPV of headache pain reliever

i)Annual Depreciation=Cost of Equipment/life

=$27/3=$9 million

ii)Statement showing after tax cash inflows for each year

Year 1($ in million) 2($ in million) 3($ in million)
[email protected] 25.50 25.50 25.50
Less:[email protected] 12.75 12.75 12.75
Net Revenue 12.75 12.75 12.75
Add:Inflation @2% 0.255 0.5151
Total Revenue 12.75 13.005 13.2651
Less:Depreciation 9.00 9.00 9.00
EBT 3.75 4.005 4.2651
Less:tax @23% 0.8625 0.92115 0.9810
EAT 2.8875 3.08385 3.2841
Add:Depreciation 9 9 9
After tax cash inflows 11.8875 12.08385 12.2841

iii)Present value of cash inflows using discount rate of 8%

=11.8875/(1+.08)^1+12.08385/(1+.08)^2+12.2841/(1+.08)^3

=$31.1184128 million

iv)NPV=Present value of cash inflows-Initial Investment

=$31.1184128 million-$27 million

=$4.1184128million

Thus NPV for headache pain reliever is 4,118,412.78


Related Solutions

After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market....
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market. It is considering two alternative products. The first is a medication for headache pain. The second is a pill for headache and arthritis pain. Both products would be introduced at a price of $9.10 per package in real terms. The headache-only medication is projected to sell 3 million packages a year, whereas the headache and arthritis remedy would sell 4.2 million packages a year....
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market....
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market. It is considering two alternative products. The first is a medication for headache pain. The second is a pill for headache and arthritis pain. Both products would be introduced at a price of $8.85 per package in real terms. The headache-only medication is projected to sell 3 million packages a year, whereas the headache and arthritis remedy would sell 4.6 million packages a year....
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market....
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market. It is considering two alternative products. The first is a medication for headache pain. The second is a pill for headache and arthritis pain. Both products would be introduced at a price of $8.60 per package in real terms. The headache-only medication is projected to sell 3 million packages a year, whereas the headache and arthritis remedy would sell 4.4 million packages a year....
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market....
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market. It is considering two alternative products. The first is to produce a medication for headache pain. The second is a pill for headache and arthritis pain. Both products would be introduced at a price of $8.85 per package in real terms. The headache-only medication is projected to sell 3 million packages a year, while the headache and arthritis remedy would sell 4.6 million packages...
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market....
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market. It is considering two alternative products. The first is to produce a medication for headache pain. The second is a pill for headache and arthritis pain. Both products would be introduced at a price of $8.85 per package in real terms. The headache-only medication is projected to sell 3 million packages a year, while the headache and arthritis remedy would sell 4.6 million packages...
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market....
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market. It is considering two alternative products. The first is a medication for headache pain. The second is a pill for headache and arthritis pain. Both products would be introduced at a price of $8.50 per package in real terms. The headache-only medication is projected to sell 3 million packages a year, whereas the headache and arthritis remedy would sell 4.7 million packages a year....
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market....
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market. It is considering two alternative products. The first is to produce a medication for headache pain. The second is a pill for headache and arthritis pain. Both products would be introduced at a price of $8.75 per package in real terms. The headache-only medication is projected to sell 2 million packages a year, while the headache and arthritis remedy would sell 4 million packages...
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market....
After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market. It is considering two alternative products. The first is to produce a medication for headache pain. The second is a pill for headache and arthritis pain. Both products would be introduced at a price of $8.90 per package in real terms. The headache-only medication is projected to sell 2 million packages a year, while the headache and arthritis remedy would sell 3.5 million packages...
1. Project Analysis and Inflation After extensive medical and marketing research, Pill, Inc., believes it can...
1. Project Analysis and Inflation After extensive medical and marketing research, Pill, Inc., believes it can penetrate the pain reliever market. It is considering two alternative products. The first is a medication for headache pain. The second is a pill for headache and arthritis pain. Both products would be introduced at a price of $8.35 per package in real terms. The headache-only medication is projected to sell 3 million packages a year, whereas the headache and arthritis remedy would sell...
MJM Ltd is considering the launch of a new product after an extensive market research whose...
MJM Ltd is considering the launch of a new product after an extensive market research whose costs were K22,000. The research cost is due for payment in a months’ time. The management accountant has prepared the following forecasts for the product. Year 1 2 3 4 K K K K Sales 220,000 200,000 180,000 120,000 Material cost. (115,000) (140,000) (110,000) (85,000) Variable overheads. (27,000) (30,000) (24,000) (18,000) Fixed overheads. (25,000) (25,000) (25,000) (25,000) Market research cost expensed. (20,000) Net profit/(loss)....
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT